"Urologists today are armed with 2 guideline-supported modalities to reduce the burden of unnecessary biopsies while maintaining timely detection of clinically significant cancers," write the authors.
Jeffrey J. Tosoian, MD, MPH
Advertisement
Tosoian is an assistant professor of urology and director of Translational Cancer Research at Vanderbilt University Medical Center in Nashville, Tennessee.
Articles by Jeffrey J. Tosoian, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
Clinical Application of MMAI Score in Patients with Prostate Cancer
2
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
3
Setting the Stage: ADT in Intermediate-Risk Prostate Cancer
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5